Ultivue Announces New Executive Team Member

Trending...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue announces the addition of Richard C. Malabre, CPA in the role of Chief Financial Officer, as the company adds to its growing executive team.

Richard is a seasoned financial professional with more than thirty years of experience in finance, accounting, internal audit, financial planning, and treasury roles. Richard was most recently the Vice President & Controller at Oxford Immunotec Global PLC a global diagnostic company, where he was responsible for the worldwide accounting, finance, and treasury functions during their initial public offering, three acquisitions, a divestiture and sale of the company. Prior to Oxford Immunotec, he held Controller and other senior financial roles at several medical device and high technology firms including Salient Surgical Technologies, Neurometrix, and Teradyne.

More on Boston Chron
Richard holds an MS from the MIT Sloan School of Management and a BA in economics from Trinity College.

Richard joins Ultivue as the company completes its Series D round of funding and looks to strengthen its position as a market leader in multiplex immunofluorescence assays for digital pathology.

"This is a very exciting time to join the Ultivue team as we continue to accelerate our growth to support our customers as they solve complex therapeutic challenges," says Richard.

"Richard carries with him the epitome of professionalism and experience," notes Jacques Corriveau, President and CEO at Ultivue. "These are crucial traits to have in a financial partner as Ultivue looks toward its future as a mainstay in the market."

About Ultivue:

Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.stats
Filed Under: Business

Show All News | Report Violation

0 Comments